Corrigendum to “Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents”

Amilton Dos Santos-Júnior,1 Taciane Barbosa Henriques,2 Maricilda Palandi de Mello,2 Osmar Henrique Della Torre,1 Lúcia Arisaka Paes,1 Adriana Perez Ferreira-Neto,1 Leticia Esposito Sewaybricker,3 Thiago Salum Fontana,1 Eloisa Helena Rubello Valler Celeri,1 Gil Guerra-Júnior,3,4 and Paulo Dalgalarrondo1

1Department of Psychiatry, School of Medical Sciences (FCM), State University of Campinas (Unicamp), 13083-887 Campinas, SP, Brazil
2Laboratory of Human Genetics, Center for Molecular Biology and Genetic Engineering (CBMEG), Unicamp, 13083-875 Campinas, SP, Brazil
3Growth and Development Laboratory, Center for Investigation in Pediatrics (CIPED), FCM-Unicamp, 13083-887 Campinas, SP, Brazil
4Department of Pediatrics, Pediatric Endocrinology Unit, FCM-Unicamp, 13083-887 Campinas, SP, Brazil

Correspondence should be addressed to Osmar Henrique Della Torre; dr.osmar.psiq@gmail.com

Received 5 January 2017; Accepted 19 April 2017; Published 16 May 2017

Copyright © 2017 Amilton Dos Santos-Júnior et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents” [1], there was an error in the “Laboratory Evaluation” section, where the selected CYP2D6 SNP is written as rs72552269, and should be corrected to “rs1065852.”

Reference
